PDI CEO: Acquisition Puts us in the Diagnostic Sweet Spot

PDI guided lower for the third quarter and full year, but CEO Nancy Lurker, says now is the time for investors to look at the company as it just made its first acquisition in the molecular diagnostic space, which has the potential for more growth and higher margins than PDI’s traditional core business and she is bullish on where the new vertical will take the company. Lurker believes the diagnostic business is indicative of what we see happening in healthcare overall with the explosion of personalized healthcare and genomics. Earlier diagnosis of disease will ultimately save the healthcare system more money and impact patient care more positively.